AbbVie price target lowered to $212 from $221 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
Optimistic Outlook on AbbVie’s Emraclidine Strategy: A High-Reward Investment Opportunity
Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...
jacobin3d
Drug Ads Misinform Patients and Raise Health Care Costs
Direct-to-consumer drug ads are prohibited in almost all countries besides the US. By leading doctors to prescribe unnecessary and more expensive treatments at the request of their patients, they also ...